Clovis Oncology Inc. (CLVS) Rating Reiterated by Stifel Nicolaus
Clovis Oncology Inc. (NASDAQ:CLVS)‘s stock had its “buy” rating reiterated by Stifel Nicolaus in a note issued to investors on Monday. They presently have a $45.00 price objective on the biopharmaceutical company’s stock. Stifel Nicolaus’ price target points to a potential upside of 40.01% from the stock’s previous close.
Other equities analysts have also issued reports about the company. SunTrust Banks Inc. increased their price objective on Clovis Oncology from $25.00 to $30.00 and gave the company a “buy” rating in a report on Wednesday, August 24th. Zacks Investment Research raised Clovis Oncology from a “hold” rating to a “buy” rating and set a $18.00 price objective for the company in a report on Thursday, August 11th. Piper Jaffray Cos. set a $14.00 price objective on Clovis Oncology and gave the company a “hold” rating in a report on Thursday, August 18th. JPMorgan Chase & Co. reissued a “hold” rating and set a $13.00 price objective on shares of Clovis Oncology in a report on Tuesday, August 9th. Finally, Credit Suisse Group AG reaffirmed a “hold” rating on shares of Clovis Oncology in a report on Tuesday, July 12th. Seven analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $36.39.
Clovis Oncology (NASDAQ:CLVS) traded up 0.60% during trading on Monday, hitting $32.00. The stock had a trading volume of 1,160,251 shares. The stock’s market capitalization is $1.23 billion. Clovis Oncology has a 52 week low of $11.57 and a 52 week high of $109.18. The company has a 50-day moving average of $31.11 and a 200-day moving average of $19.16.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/17/clovis-oncology-inc-clvs-rating-reiterated-by-stifel-nicolaus.html
Clovis Oncology (NASDAQ:CLVS) last announced its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($2.07) earnings per share for the quarter, beating the consensus estimate of ($2.13) by $0.06. During the same period in the prior year, the business earned ($2.10) EPS. On average, equities analysts expect that Clovis Oncology will post ($9.25) earnings per share for the current fiscal year.
A number of large investors have recently added to or reduced their stakes in the stock. ProShare Advisors LLC increased its stake in Clovis Oncology by 3.2% in the second quarter. ProShare Advisors LLC now owns 33,584 shares of the biopharmaceutical company’s stock worth $461,000 after buying an additional 1,056 shares during the last quarter. State Board of Administration of Florida Retirement System increased its stake in Clovis Oncology by 8.0% in the second quarter. State Board of Administration of Florida Retirement System now owns 22,819 shares of the biopharmaceutical company’s stock worth $313,000 after buying an additional 1,693 shares during the last quarter. Rice Hall James & Associates LLC increased its stake in Clovis Oncology by 1.8% in the second quarter. Rice Hall James & Associates LLC now owns 94,594 shares of the biopharmaceutical company’s stock worth $1,298,000 after buying an additional 1,716 shares during the last quarter. American International Group Inc. increased its stake in Clovis Oncology by 12.4% in the second quarter. American International Group Inc. now owns 18,297 shares of the biopharmaceutical company’s stock worth $251,000 after buying an additional 2,016 shares during the last quarter. Finally, Spark Investment Management LLC increased its stake in Clovis Oncology by 2.3% in the first quarter. Spark Investment Management LLC now owns 112,500 shares of the biopharmaceutical company’s stock worth $2,160,000 after buying an additional 2,500 shares during the last quarter. Institutional investors and hedge funds own 98.50% of the company’s stock.
Clovis Oncology Company Profile
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M.
Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.